Talphera (TLPH) Projected to Release Earnings on Thursday

Talphera (NASDAQ:TLPH) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.0625) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Talphera (NASDAQ:TLPH) last released its earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. On average, analysts expect Talphera to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Talphera Stock Up 4.3%

Shares of Talphera stock opened at $1.47 on Wednesday. Talphera has a 52-week low of $0.40 and a 52-week high of $1.57. The company has a 50 day moving average of $1.16 and a 200 day moving average of $0.95. The company has a market capitalization of $76.29 million, a P/E ratio of -4.74 and a beta of 0.69.

Analysts Set New Price Targets

A number of brokerages have commented on TLPH. HC Wainwright initiated coverage on shares of Talphera in a research report on Friday, June 5th. They issued a “buy” rating and a $3.00 price objective on the stock. Zacks Research raised shares of Talphera to a “hold” rating in a research report on Monday, June 8th. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Friday, July 17th. Finally, Westpark Capital started coverage on Talphera in a report on Thursday, April 30th. They issued a “buy” rating and a $3.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Talphera currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Talphera

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cantor Fitzgerald L. P. purchased a new position in Talphera in the fourth quarter valued at approximately $658,000. Diadema Partners LP purchased a new stake in shares of Talphera during the 4th quarter worth approximately $156,000. Persistent Asset Partners Ltd purchased a new stake in shares of Talphera during the 4th quarter worth approximately $42,000. Mariner LLC boosted its holdings in shares of Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after buying an additional 33,000 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Talphera by 412.6% in the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after buying an additional 207,166 shares in the last quarter. 37.67% of the stock is owned by institutional investors and hedge funds.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.